

1 **Title:** Hyaluronan in COVID-19 morbidity, a bedside-to-bench approach to understand
2 mechanisms and long-term consequences of hyaluronan.

3 Urban Hellman^{1,2}, Ebba Rosendal^{1,3}, Joakim Lehrstrand⁴, Johan Henriksson^{3,5}, Tove Björnell⁶,
4 Max Hahn⁴, Björn Österberg⁷, Luiza Dorofte⁸, Emma Nilsson^{1,3}, Mattias N.E. Forsell¹, Anna
5 Smed-Sörensen⁷, Anna Lange⁹, Mats Karlsson⁸, Clas Ahlm¹, Anders Blomberg², Sara
6 Cajander⁹, Ulf Ahlgren⁴, Alicia Edin¹⁰, Johan Normark^{1,11} Anna K Överby^{1,3*} and Annasara
7 Lenman^{1*}

8 ¹Department of Clinical Microbiology, Umeå University, Umeå, Sweden

9 ²Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden

10 ³The laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå University, Umeå,
11 Sweden

12 ⁴Umeå Centre for Molecular Medicine (UCMM), Umeå University, Umeå, Sweden

13 ⁵Department of Molecular Biology, Umeå Centre for Microbial Research (UCMR), and Icelab,
14 Umeå University, Umeå, Sweden

15 ⁶Centre for Clinical Research and Education, Region Värmland, Karlstad, Sweden

16 ⁷Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet,
17 Karolinska University Hospital, Stockholm, Sweden

18 ⁸Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University,
19 Örebro, Sweden

20 ⁹Department of Infectious Diseases, Faculty of Medicine and Health, Örebro University,
21 Örebro, Sweden

22 ¹⁰ Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden.

23 ¹¹Wallenberg Centre for Molecular Medicine, Umeå University, Sweden

24 **These authors contributed equally*

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25

26 Correspondence and requests for reprints should be addressed to Ph.D. Annasara Lenman,
27 Department of Clinical Microbiology, Umeå University, Umeå, Sweden. Email:
28 annasara.lenman@umu.se or Prof. Anna K Överby Department of Clinical Microbiology,
29 Umeå University, Umeå, Sweden. Email: anna.overby@umu.se

30

31 **Author contributions:** U.H., E.R., C.A., A.B., A.K.Ö and A.Le designed the study. U.H., E.R.,
32 J.L, M.H., E.N., U.A. and A.Le conducted experiments and analyzed the results. T.B, B.Ö L.D.,
33 M.F., A.SS., A.La., M.K, S.C., J.N and A.E. performed inclusion and sampling of patients,
34 collected, managed, and analyzed clinical data. J.H. analyzed transcriptomics data. U.H., A.E,
35 C.A., A.B., A.K.Ö., and A.Le. wrote the manuscript with input from all authors.

36

37 **This study was supported by:** the Swedish Heart-Lung Foundation (20200385 to A.K.Ö &
38 A.L., 20200325 & 20210078 to C.A., and 20200366 & 20210049 to A.B.), SciLife Lab
39 COVID-19 research program funded by the Knut and Alice Wallenberg Foundation (2020.0182
40 & C19R:028 to A.K.Ö. & A.L., and VC-2020-0015 to C.A.), Kempestiftelserna (grant no. JCK-
41 1827 to A.K.Ö.), Umeå University and County Council of Västerbotten (#RV-938855 to C.A.
42 and #RV-970074 to A.K.Ö.), Carl Bennet AB (A.L.), the Fundraising Foundation for Medical
43 Research, Umeå University (978018 to A.L. and 964781 to U.H.), Nyckelfonden Örebro (OLL-
44 938628, OLL-961416 to S.C.), Regional Research Council Mid Sweden (RFR-968856, RFR-
45 940474 to S.C), the Swedish Research Council (2020-06235 to M.N.E.F, 2016-06514 to J.N.,
46 2021-06602 to J.H.), J.N. is a Wallenberg Centre for Molecular Medicine Associated
47 Researcher. Computations were performed using resources provided by SNIC through Uppsala
48 Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project SNIC
49 2021/22-697 to J.H. Apart from funding, the sponsors were not involved in performing the
50 present study.

51 **ABSTRACT**

52 **Background:** We have previously shown that lungs from deceased COVID-19 patients are
53 filled with hyaluronan (HA). In this translational study, we investigated the role of HA in all
54 stages of COVID-19 disease, to map the consequences of elevated HA in morbidity and identify
55 the mechanism of SARS-CoV-2-induced HA production.

56 **Methods:** Lung morphology was visualized in 3D using light-sheet fluorescence microscopy.
57 HA was verified by immunohistochemistry, and fragmentation was determined by gas-phase
58 electrophoretic molecular mobility analysis. The association of systemic HA in blood plasma
59 and disease severity was assessed in patients with mild (WHO Clinical Progression Scale,
60 WHO-CPS, 1-5) and severe COVID-19 (WHO-CPS 6-9), during the acute and convalescent
61 phases and related to lung function. *In vitro* 3D-lung models differentiated from primary human
62 bronchial epithelial cells were used to study effects of SARS-CoV-2 infection on HA
63 metabolism.

64 **Findings:** Lungs of deceased COVID-19 patients displayed reduced alveolar surface area
65 compared to healthy controls. We verified HA in alveoli and showed high levels of fragmented
66 HA both in lung tissue and aspirates. Systemic levels of HA were high during acute COVID-
67 19 disease, remained elevated during convalescence and associated with reduced diffusion
68 capacity. Transcriptomic analysis of SARS-CoV-2-infected lung models showed dysregulation
69 of HA synthases and hyaluronidases, both contributing to increased HA in apical secretions.
70 Corticosteroid treatment reduced inflammation and, also, downregulated HA synthases.

71 **Interpretation:** We show that HA plays a role in COVID-19 morbidity and that sustained
72 elevated HA concentrations may contribute to long-term respiratory impairment. SARS-CoV-
73 2 infection triggers a dysregulation of HA production, leading to increased concentrations of
74 HA that are partially counteracted by corticosteroid treatment. Treatments directly targeting

- 75 HA production and/or degradation can likely be used early during infection and may alleviate
- 76 disease progression and prevent long-term lung complications.

77 INTRODUCTION

78 The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-
79 CoV-2) has hitherto caused more than 6.8 million reported deaths globally (by March 22, 2023,
80 according to WHO). The clinical manifestations of COVID-19 range from asymptomatic or
81 mild disease with symptoms from the upper respiratory tract to severe pneumonitis with acute
82 respiratory distress syndrome (ARDS) and multiorgan failure. Several pathophysiological
83 mechanisms have been described as contributing to respiratory failure in COVID-19, including
84 hyperinflammation with disturbed coagulation, leading to disseminated pulmonary
85 microthrombi as well as diffuse alveolar damage, alveolar septal fibrous proliferation and
86 pulmonary consolidation (1, 2).

87

88 Hyaluronan (HA) is a glycosaminoglycan that constitutes an important structural component of
89 the extracellular matrix in tissues. Through interactions with cell-surface receptors, HA also
90 regulates cellular functions, such as cell-matrix signaling, cell proliferation, angiogenesis and
91 cell migration (3). HA is often present in its high molecular weight structure in healthy tissue
92 and has an anti-inflammatory effect (4). In contrast, low molecular weight HA has been shown
93 to have a pro-inflammatory effect when HA fragments bind to toll-like receptors and induce
94 NF- κ B signaling (5). HA also influences the development of fibrosis by affecting fibroblast
95 proliferation, differentiation, and motility (6).

96

97 In addition, HA has a very high water-binding capacity, with the ability to occupy large
98 hydrated volumes up to 1,000 times its molecular mass, which can promote edema formation
99 (3). Accumulation of HA is associated with ARDS (7), and recent publications have shown
100 increased levels of HA in the lungs of deceased COVID-19 patients (8, 9) as well as elevated
101 plasma levels of HA in severe cases (10, 11). Anti-inflammatory treatment with the

102 corticosteroid dexamethasone results in lower mortality amongst hospitalized COVID-19
103 patients (12). Corticosteroids are known to be effective in reducing HA levels in other
104 inflammatory syndromes (13, 14), thus, clearance of HA may be critical in disease resolution
105 following COVID-19 (8). We recently found that severe COVID-19 is an important risk factor
106 for impaired respiratory function, characterized by a decrease in diffusion capacity (DL_{CO}), 3-
107 6 months after the infection (15). However, if the lung function correlates with systemic HA is
108 currently not clear.

109

110 Here we set out to investigate HA at all stages of COVID-19 disease, from acute infection to
111 convalescence in mild, severely ill and fatal cases. Our aim was to understand molecular
112 mechanisms involved in the pathological overproduction of HA in disease and pathogenicity.
113 In addition, we established an *in vitro* 3D-lung model to investigate the impact of SARS-CoV-
114 2 infection on HA metabolism as well as the role of corticosteroid treatment to define molecular
115 disease mechanisms.

116

117 **RESULTS**

118 **Morphological differences induced by COVID-19 visualized by light sheet fluorescent** 119 **microscopy.**

120 We have previously shown that the lungs of fatal COVID-19 patients are filled with HA (8).
121 However, it is not clear which consequences HA has on the structural integrity of the lung and
122 the alveolar volume. To address this, we set out to morphologically determine the three-
123 dimensional organization within lung biopsies with light sheet fluorescence microscopy
124 (LSFM). These biopsies originated from three deceased COVID-19 patients, four healthy
125 donors who underwent lung resection, and one patient who underwent lung resection ten weeks
126 post intensive care treatment due to severe COVID-19 infection, here referred as recovered.

127 The lung biopsies were processed, cleared and subjected to LSM visualizing the
128 autofluorescence (figure 1A). Major differences in the morphology of the lung were detected
129 by maximum intensity projection (figure 1B-D, supplementary figure 1, and supplementary
130 movie 1-3). The lungs of fatal COVID-19 patients were considerably denser compared to the
131 healthy controls and recovered lung. Optical sections of the tissue revealed thin alveolar walls
132 in the controls and recovered, whereas the distances between the alveoli in COVID-19 lungs
133 were larger (figure 1E-G). The size distribution of the alveoli diameter was also smaller in the
134 COVID-19 compared to control and recovered lung (figure H). The number of empty alveoli
135 was fewer in the COVID-19 lungs as visualized in the surface rendering of the alveolar space
136 (figure 1I-K). Next, the surface of the alveoli was quantified to better understand the capacity
137 of the gas exchange in the samples. The isosurfaces of the alveoli were determined and showed
138 a major loss of alveoli surface in the COVID-19 lungs compared to the healthy controls (figure
139 1L). Worth noting is that the lung morphology found in the recovered COVID-19 patient
140 showed high similarity to the healthy controls.

141

142 To confirm the presence of HA in alveoli and to see if there is a difference in accumulation
143 between the upper and lower lung lobes, histochemistry was performed on five COVID-19
144 necropsies (figure 2A-B). We did not observe a major difference between patients or lung
145 regions, but extensive accumulation of HA was seen in COVID-19 necropsy compared to
146 healthy controls (figure 2C). Collagen coils, a marker for irreversible lung damage, were also
147 found in large areas of the necropsy where no remains of alveolar walls could be detected
148 (figure 2C).

149

150

151

152 **Severe COVID-19 induces fragmentation of HA in lung tissue and aspirates**

153 As fragmented low molecular HA increases at sites of active inflammation and display a
154 proinflammatory activity, HA fragmentation likely contributes to disease progression of
155 COVID-19. HA was extracted from necropsies derived from the upper, and lower left lobe of
156 five COVID-19 patients to investigate this. The isolated HA was subjected to size determination
157 analysis by gas-phase electrophoretic mobility molecular analysis (GEMMA). Both the upper
158 and lower lung lobes displayed highly fragmented HA (figure 2D). Although we did not observe
159 an apparent difference in the abundance of HA with histochemistry between the upper and
160 lower lung lobes (figure 2B), we found higher levels of both total HA and fragmented HA in
161 the lower parts of the lung with GEMMA (figure 2D, area under the curve). Since fragmented
162 HA induces a proinflammatory state and initiates migration of immune cells (16), we analysed
163 the presence of neutrophils in lungs by staining for elastase. We detected major neutrophil
164 infiltration in COVID-19 lungs compared to uninfected controls (supplementary figure 2).
165 Next, nasopharyngeal aspirates (NPA) and endotracheal aspirates (ETA) collected from three
166 COVID-19 patients were analysed to investigate the fragmentation process of HA during
167 ongoing severe disease. All patients displayed fragmented HA, however, in contrast to the
168 fragmentation in the necropsy samples, there were large individual variations between the total
169 amount and degree of fragmentation (figure 2E-F). The finding that HA accumulated in the
170 lungs and aspirates of severely diseased patients prompted us to measure the systemic levels of
171 HA. We performed this in a cohort of mild and severely ill patients during acute disease and
172 convalescence. Our objective was to investigate if plasma concentrations of HA could be used
173 as a biomarker for disease severity.

174

175

176 **Hyaluronan levels in plasma increase in severe COVID-19 and correlate with a reduction**
177 **in lung function at follow up**

178 Patients with COVID-19 infection classified as severe, based on requirement of high-flow nasal
179 oxygen treatment and/or admission to the intensive care unit (ICU) corresponding to WHO-
180 CPS 6-10 (17), were matched according to age to patients with mild COVID-19 (WHO-CPS 1-
181 5). In total 103 individuals were selected; 37 patients were classified as severe and 66 patients
182 as mild. The demography and clinical characteristics are presented in table 1. The groups
183 differed significantly in BMI, obesity, minimum levels of hemoglobin, maximum levels of C-
184 reactive protein, white blood cell count, and neutrophil count. No significant differences were
185 observed when it came to comorbidities at baseline. Thirty-two (86.5%) patients in the severe
186 group and four (6.1%) in the mild group received corticosteroid treatment ($p < 0.001$). Most of
187 these patients, 28 in the severe and two in the mild group, received the first dose before the first
188 sampling timepoint.

189
190 The concentration of HA in plasma samples was determined using ELISA in order to assess the
191 association between HA and disease severity. A general increase in HA concentrations was
192 observed in samples taken during the acute phase of the disease in both patients with mild and
193 severe COVID-19, as compared to healthy controls (figure 3A). The HA concentrations were
194 even further increased in patients with severe COVID-19. Interestingly, although HA
195 concentrations declined in the convalescent phase (mild $p < 0.0001$, severe $p < 0.0001$), they
196 remained elevated compared to healthy controls, especially in patients with severe disease. A
197 sex comparison of HA plasma concentrations in the acute phase showed a similar increase in
198 HA in severe COVID-19 in women and men (figure 3B). However, the HA levels remained
199 higher among women compared to men ($p=0.043$, data not shown) in the convalescent phase
200 of mild COVID-19. Analyses assessing the impact of age showed an increase in HA

201 concentrations in severe compared to mild COVID-19 in both older (60-89 years) and younger
202 (18-59 years) patients, with a general trend towards higher HA concentrations in the older age
203 group (mild disease: $p=0.01$, severe disease: $p=0.17$) (figure 3C). As we have seen that HA
204 accumulated in the lungs during COVID-19, and systemic levels of HA remains high even after
205 12 weeks, we next wanted to investigate how the systemic HA levels would correlate to actual
206 lung function. HA levels of acutely infected patients were associated with the percentage of
207 predicted diffusion capacity ($DL_{CO}\%pred$) three to six months after infection (figure 3D-G).
208 Lung function measurements were available in 70 out of 103 patients. The analysis was adjusted
209 for sex, chronic lung disease, cardiovascular disease, hypertension, diabetes, smoking (current
210 or previous), obesity ($BMI \geq 30$), severity of COVID-19 (mild or severe), and age (20-59 and
211 60-89 years). Our results showed a negative correlation between HA levels in both the
212 convalescent phase and acute phase with $DL_{CO}\%pred$ (supplementary table 1 and 2).

213

214 In summary, plasma concentrations of HA were substantially increased in COVID-19 patients
215 and correlated to disease severity and reduced diffusion capacity. We then performed infection
216 experiments in a human 3D-lung model to further study the potential mechanisms behind the
217 increase of HA in COVID-19.

218

219 **SARS-CoV-2 infection causes an inflammatory response, which is counteracted by** 220 **corticosteroids in a human 3D-lung model**

221 We used a lung model that closely resembles the human respiratory tract based on primary
222 human bronchial epithelial cells (HBECs) isolated from human donors. This model was used
223 to characterize the cellular pathways affected by SARS-CoV-2 infection and the effects of
224 corticosteroid treatment with respect to inflammation and HA metabolism. The cells were
225 differentiated at an air-liquid interface (ALI) to form a polarized epithelium containing an apical

226 layer of fully functional secretory and ciliated cells and an underlying layer of basal cells (18).
227 The lung cultures were treated with, or without, the corticosteroid betamethasone, and infected
228 with SARS-CoV-2 (figure 4A). The course of infection was monitored daily by collection of
229 apical secretions containing released progeny virus and the viral load was quantified by qPCR.
230 A distinct increase in viral RNA was observed over time, indicating an active viral replication
231 in the HBEC ALI-cultures (figure 4B). Betamethasone-treated cultures showed reduced levels
232 of released progeny virus. The infected HBEC ALI-cultures were harvested at 96h post
233 infection and subjected to total RNA sequencing, to identify the mechanisms and pathways
234 regulated by SARS-CoV-2 infection and betamethasone treatment. Statistical comparison of
235 genes expressed in uninfected vs. infected HBEC ALI-cultures (figure 4C, supplementary table
236 3) identified 167 differentially expressed genes (DEGs) that were upregulated upon SARS-
237 CoV-2 infection, with a strong enrichment of genes involved in the immune response,
238 especially type I interferon (IFN-I) signaling. A similar statistical comparison of infected HBEC
239 ALI-cultures with or without betamethasone treatment was performed to evaluate the effect of
240 betamethasone treatment. This identified 102 genes that were upregulated, and 229 genes that
241 were downregulated in the betamethasone-treated cultures (figure 4D, supplementary table 3).
242 Interestingly, 73 of the 167 genes upregulated by infection (figure 4C) were downregulated by
243 betamethasone treatment (figure 4D). A heatmap displaying the mean expression values of the
244 individual overlapping genes showed a clear upregulation of these genes by SARS-CoV-2
245 infection, which was counteracted by betamethasone treatment (figure 4E). Several of the
246 affected genes were involved in inflammatory responses, correlating well with the anti-
247 inflammatory activity of betamethasone. We also collected basolateral samples from the HBEC
248 ALI-cultures at 96h post infection and analyzed these with a targeted cytokine panel based on
249 proximity extension assay, allowing a quantitative concentration measurement of each cytokine
250 (figure 4F). Of the ten cytokines that showed significant changes, eight were downregulated by

251 betamethasone treatment, but not affected by the infection. CXCL10 and CXCL11 were both
252 upregulated by the SARS-CoV-2 infection and subsequently downregulated by steroid
253 treatment.

254

255 **SARS-CoV-2 affects HA metabolism by upregulation of HA synthases and**
256 **downregulation of hyaluronidases**

257 To further investigate the direct effect of SARS-CoV-2 on HA synthesis and degradation,
258 expression levels of the three human hyaluronan synthases, *HAS1*, *HAS2* and *HAS3* and the two
259 major hyaluronidases, *HYAL1* and *HYAL2*, were determined in HBEC ALI-cultures from two
260 different donors five days post infection. No effect was seen on *HAS1* expression, but SARS-
261 CoV-2 infection increased *HAS2* in donor 2 and *HAS3* expression in both donors (figure 4G-I).
262 Betamethasone treatment of infected cultures resulted in a reduction of the upregulated *HAS2*
263 expression in donor 2 and *HAS3* in donor 1 (figure 4H and I). Additionally, SARS-CoV-2
264 infection decreased expression of hyaluronidase *HYAL1* in both donors and *HYAL2* in donor 2
265 (figure 4J and K). The hyaluronidase genes were not significantly affected by betamethasone
266 treatment (figure 4J and K). Both upregulation of HA synthases and downregulation of
267 degrading hyaluronidases can induce an increase in HA concentrations. Indeed, measurements
268 of HA concentrations in the apical secretions from HBEC ALI-cultures confirmed the
269 transcriptional changes with an increase in HA in cultures infected by SARS-CoV-2, which
270 were kept at baseline concentrations when simultaneously treated with betamethasone (figure
271 4L).

272

273 Taken together, our results identified genes involved in viral defense and inflammation affected
274 by SARS-CoV-2 infection. Betamethasone treatment demonstrated a general counteraction
275 against the viral transcriptional effect. SARS-CoV-2 infection and betamethasone treatment

276 also affected genes with potential impact on HA production and degradation. In addition to the
277 effects on HA synthases and hyaluronidases, we observed an upregulation of transcription
278 factors early growth response 1 and 2 (*EGRI*, 2) upon SARS-CoV-2 infection and a
279 downregulation of lactate dehydrogenase A (*LDHA*) and TP53 induced glycolysis regulatory
280 phosphatase (*TIGAR*) after betamethasone treatment, all of which are involved in the glycolysis
281 and therefore affect HA metabolism (supplementary table 3). Based on our results, we present
282 a model where the positive action of betamethasone in severe COVID-19 patients is a combined
283 action of a reduced inflammatory response (figure 5A, supplementary table 3) and a reduction
284 of the pathological overproduction of HA upon SARS-CoV-2 infection (figure 5B,
285 supplementary table 3).

286

287 **DISCUSSION**

288 We have previously shown that lungs from deceased COVID-19 patients are filled with a clear
289 liquid jelly consisting of HA, which impairs the capillary-alveolar gas exchange and leads to
290 respiratory failure. In this study, we investigated the morphology of the lung in 3D, the presence
291 of fragmented HA during severe COVID-19 and the correlation between systemic HA levels
292 and diffusion capacity of the lungs after recovery. We also show the mechanisms behind the
293 pathological increase in HA levels, which were counteracted by corticosteroid treatment, to
294 possibly identify new therapeutic targets using a human *in vitro* 3D-lung model.

295

296 Morphological studies of tissue are commonly done by immunohistochemistry of thin tissue
297 slices. These have the advantage of a high resolution down to subcellular level, and many
298 cellular markers can be used to identify different features. However, it is much more difficult
299 to analyze the composition and morphology of lung tissue especially the alveolar volume or
300 surface areas. We therefore used LSM to study the morphology of lung necropsies and

301 biopsies in 3D. Our results showed a reduction in the number and size of the alveoli, as well as
302 the surface area used for gas exchange at end stage of COVID-19 compared to healthy controls.
303 Interestingly, LSFM has been used previously in a ferret model of COVID-19, but no similar
304 obstructions were seen in their lungs (19). With histochemistry we showed that the alveoli were
305 filled with HA and this HA was highly fragmented in the COVID-19 necropsies, likely
306 contributing to the inflammatory milieu visualized by large infiltrates of neutrophils. The HA
307 was also fragmented in severe COVID-19 in both nasopharyngeal and endotracheal aspirates.
308 Interestingly, hyper-induction of HA in the lungs appears in many respects to be a reversible
309 process. Even though reduced diffusion capacity correlates to disease severity (15) and is
310 related to severity of radiologic lung involvement at admission (20), there is still restitution.
311 This is supported by our data where the recovered COVID-19 patient did not present with a
312 reduced mean alveolar surface area compared to the healthy controls. However, the presence of
313 collagen coils that disrupt alveolar walls in necropsy COVID-19 lungs suggests that the filling
314 of HA in the alveoli precedes the development of collagen fibrosis and irreversible lung
315 damage. This is supported by previous findings in both human inflammatory diseases and in a
316 lung damage rat model (6, 21, 22). The role of HA size in fibrosis is not clear, but it has been
317 demonstrated that the interaction of fragmented HA and the receptor HA-mediated motility
318 receptor (RHAMM), increased the infiltration of fibroblasts, leading to uncontrolled wound
319 healing with collagen production and fibrosis (23).

320

321 We showed that despite an overall reduction in systemic HA concentrations during the
322 convalescent phase (≥ 12 weeks), the plasma levels did not normalize in either mild or severe
323 COVID-19 patients and remained significantly higher compared to the control group. Prior
324 studies have demonstrated an elevation of HA concentration associated with disease severity in
325 the acute phase of COVID-19 (10, 11), but the long-term consequences of COVID-19 on HA

326 levels have not previously been thoroughly investigated. The tissue half-life of HA ranges from
327 half a day to two-three days, and the half-time in blood is even shorter (24). The sustained
328 elevation of plasma HA concentrations demonstrated here therefore suggests an imbalance in
329 the production and degradation of HA that remains for at least 12 weeks after disease onset,
330 even after mild disease. The correlation of high plasma levels of HA in both acute and
331 convalescent phase with reduced diffusion capacity also implies that plasma HA may be used
332 as a predictive biomarker for future lung function impairment.

333

334 The molecular mechanisms behind the observed increase in HA synthesis upon SARS-CoV-2
335 infection remain to be clarified. Based on the results of this study, we here propose a model in
336 which SARS-CoV-2 infection causes transcriptional changes of genes involved in HA
337 metabolism, which are partially counteracted by corticosteroid treatment. In our human *in vitro*
338 3D-lung model, SARS-CoV-2 infection caused an upregulation of the transcription factors
339 *EGR1* and *EGR2*, which in turn activated the expression of HA synthases *HAS2* and *HAS3*. At
340 the same time, SARS-CoV-2 infection decreased the degrading hyaluronidases. However, it is
341 possible that additional pathways can affect HA production. It was recently shown that specific
342 RNA sequences in the SARS-CoV-2 genome can activate expression of *HAS2* and,
343 consequently, increase HA synthesis (25). In addition, changes to the glycolysis pathway may
344 affect HA levels, due to an increased production of HA precursor molecules (26). Interestingly,
345 others have shown that SARS-CoV-2 infection and subsequent replication induce an increased
346 glucose metabolism in infected cells (27, 28). Corticosteroid treatment reduced the overall HA
347 concentration in our 3D-lung model during SARS-CoV-2 infection. Interestingly, besides
348 counteracting the SARS-CoV-2-induced effect on hyaluronan synthases, corticosteroid
349 treatment of the infected 3D-lung model also decreased the expression of lactate dehydrogenase

350 A (LDHA) and TIGAR, which may both contribute to decreased HA production via the
351 glycolysis pathway (29, 30).

352

353 Today, one of the few evidence-based treatment options for patients with severe to critical
354 COVID-19 is corticosteroids (12). However, the timing of treatment seems to be crucial. Early
355 treatment of COVID-19 patients with corticosteroids has been shown to have less positive effect
356 than treating severely ill patients (12). The increased levels of HA in the blood from both mild
357 and severe cases of COVID-19, shown by us and others (10, 11), indicate a dysregulated HA
358 metabolism in COVID-19, which was also supported by the findings in our 3D-lung model.
359 Hyaluronan production and/or degradation therefore poses an attractive treatment target for
360 severe COVID-19. Hymecromone, an FDA-approved drug for treatment of biliary spasm, has
361 a more direct action against HA synthesis and could be used to specifically treat the
362 overproduction of HA. Such a high-precision treatment could avoid some of the negative effects
363 of corticosteroids and enable treatment at an earlier stage to prevent disease progression. A
364 recent clinical trial with hymecromone showed efficient inhibition of COVID-19 progression
365 and warrants further investigations (31).

366

367 In summary, our results showed destructed lung morphology with markedly decreased gas
368 exchange surface in COVID-19, fragmented inflammatory HA in both nasopharyngeal aspirate
369 and endotracheal aspirate and sustained increased levels of HA in peripheral blood in COVID-
370 19 patients. The increased HA expression could be explained by the mechanisms identified in
371 our *in vitro* lung model including an imbalance in HA production and degradation induced upon
372 SARS-CoV-2 infection. We also show that elevated systemic HA levels both in acute COVID-
373 19 and convalescence phase negatively correlate with diffusion capacity in the lungs during
374 convalescence. Further studies are needed to evaluate systemic HA as a biomarker for long term

375 lung function impairment. We show that HA is an important factor in COVID-19 pathogenesis,
376 and studies on targeting HA metabolism as an alternative or complementary treatment to
377 corticosteroids to reduce the acute and long-term health consequences of COVID-19 are
378 warranted.

379

380 **METHODS**

381 **Tissue pre-processing for optical 3D-imaging**

382 Lung biopsies from four healthy controls, three deceased COVID-19 patients and one patient
383 that recovered from COVID-19 were washed in PBS, fixed in formalin overnight, dehydrated
384 successively into methanol (MeOH) (25%, 50%, 75%, 100%, 15 min each step) and stored at -
385 20°C until use. Prior to clearing, the lung samples were treated in bleaching solution (H₂O₂:
386 dimethyl sulfoxide: MeOH, 3:1:2) overnight at room temperature (RT). The bleaching solution
387 was refreshed, and the samples were incubated for an additional 6 hours at RT. Following
388 bleaching, the samples were rehydrated into PBS (25%, 50%, 75%, 100%, 15 min each step)
389 and mounted in 1.5% low-melting point agarose (Lonza™ SeaPlaque™ Agarose, Lonza, USA).
390 After solidifying overnight, the agarose pieces were cut into cuboids and dehydrated into MeOH
391 (25%, 50%, 75%, 100%, 15 min each step). The samples were subsequently washed in MeOH
392 for 2x24 hours on rotation in order to remove any residual water. Following MeOH washes, the
393 samples were optically cleared in BABB (benzyl alcohol, benzyl benzoate, 1:2) changing
394 solution every 12 hours until the biopsies were completely cleared.

395

396 **Light sheet fluorescence microscopy and 3D image processing**

397 High resolution 3D images of the lungs were acquired using a UltraMicroscope II (Miltenyi
398 Biotec, Germany) fitted with an 1x Olympus objective (Olympus PLAPO 2XC) and a lens
399 corrected dipping cap MVPLAPO 2x DC DBE objective attached to an Olympus MVX10 zoom

400 body with a 3000 step chromatic correction motor. The lung regions of interest were captured
401 at a magnification of 1.6x with a scan depth of 1000 μm , a dynamic focus range across the
402 specimen capturing 10 images per section, and a step-size of 5 μm yielding a voxel size of 1.89
403 x 1.89 x 5 μm . The samples were scanned for autofluorescence with the filters: Ex 470/40, Em:
404 525/50 using an exposure time of 300ms. Optical sections were saved in *.ome.tif format native
405 to the InspectorPro software (version 7.0.124.9 LaVision Biotex GmbH, Germany). The
406 *.ome.tif files were converted into 3D projection *.ims files using the Imaris file converter
407 (version 9.9.1, Bitplane, UK) 3D volumes were generated using the built in surfacing method
408 of Imaris (version 9.8.0, Bitplane, UK). To quantify the “empty space volume”, roughly
409 translating to the alveolar volume, the threshold was set to only include hypointense space using
410 absolute intensity for surfacing, with a surface grain size set to 0.8 μm . Further, an exclusion
411 filter removing objects consisting of less than 10 voxels was applied to remove general noise.
412 The anatomy surface was generated and set to include all signal above the hypointense signal
413 with a surface grain size of 3.78 μm and a 10 voxel exclusion filter. Surfaces generated from
414 hypointense regions outside the tissue volume were manually excluded when possible.
415 Volumes and area of the segmented surfaces were extracted from Imaris as Excel (Microsoft,
416 Office 365, version 2301) *.XML file format for quantification.

417

418 **Isolation and fragmentation of HA from lung biopsies and aspirates**

419 *(i) HA isolation*

420 Cellular secrets were dried in a Savant SpeedVac DNA 110 vacuum concentrator (Thermo
421 Fisher Scientific, MA, USA). Proteins and nucleic acids were digested with proteinase K
422 (Sigma-Aldrich, St Louis, MO, USA) and benzonase nuclease (Sigma-Aldrich) on two
423 consecutive days. At the end of each digestion, chloroform was added to each sample and the
424 extracted aqueous phase was solvent exchanged to 0.1 M NaCl using Amicon Ultra 3K

425 concentration units (Millipore, Billerica, MA, USA) followed by overnight precipitation in 99%
426 ethanol. Sulphated glycosaminoglycans and remaining non-HA contaminants were removed
427 with anion-exchange mini spin columns (Thermo Fisher Scientific, MA, USA), based on NaCl
428 binding. Finally, to remove salt the sample was solvent exchanged to 20 mM ammonium acetate
429 (pH 8.0) in Amicon Ultra 3K concentration units.

430

431 *(ii) HA molecular mass analysis*

432 HA mass analysis was undertaken using a gas-phase electrophoretic mobility molecular
433 analysis (GEMMA) (TSI Corp., MN, USA). The molecule diameter analyzed in the GEMMA
434 was converted to molecular mass by analyzing HA standards ranging from 30 kDa to 2500 kDa
435 (Hyalose, OK, USA). The area under the curve corresponds to the number of molecules in the
436 GEMMA analysis.

437

438 **Study design and study population**

439 Data and clinical samples were obtained from the CoVUm study, a prospective, multicenter
440 observational study of COVID-19 including patients from Umeå and Örebro, and coordinated
441 from Umeå University, Sweden (www.clinicaltrials.gov identifier NCT 04368013). The study
442 protocol and cohort have been described in detail earlier (32). Non-hospitalized patients aged
443 ≥ 15 years and hospitalized patients aged ≥ 18 years with a positive PCR-test for SARS-CoV-2
444 were enrolled in the study. Written informed consent was obtained from all participants or their
445 next of kin before the first sampling timepoint. At data export on May 4, 2022, a total of 543
446 participants, enrolled between 27 April 2020 and 28 May 2021, had been registered in the
447 CoVUm database. Seven of the participants were excluded since they did not fulfill the
448 inclusion criteria (false positive PCR-tests for SARS-CoV-2). Out of the remaining 536
449 participants, all patients classified as severely ill during the acute phase of the disease, and with

450 available blood samples, were selected for this study. In addition, 66 patients with mild COVID-
451 19 were selected from the remaining study cohort. Participants were classified as “severe” if
452 they required high-flow nasal oxygen treatment (HFNO) and/or was admitted to the intensive
453 care unit (ICU) during the acute phase of illness, corresponding to WHO Clinical Progression
454 Scale (WHO-CPS) 6-10 (17). All other participants were classified as “mild”, corresponding to
455 WHO-CPS 1-5. Blood samples were obtained at acute phase (0-4 weeks after onset) and
456 convalescent phase (≥ 12 weeks). For study outline, see figure 2A. A healthy control group,
457 consisting of plasma samples collected from anonymous blood donors was included for
458 reference. The study was performed according to the Declaration of Helsinki and approved by
459 the Swedish Ethical Review Authority.

460

461 **Data collection and clinical samples**

462 All clinical metadata including age, sex, Charlson Comorbidity Index (CCI) (33), tobacco use,
463 medication at enrollment, body mass index, type of respiratory support and medical treatment
464 were collected and managed using the REDCap electronic data capture tools hosted at Umeå
465 University (34, 35). Clinical chemistry data of conventional inflammatory markers were
466 extracted retrospectively from the patients’ electronic medical records. The highest and lowest
467 values of each biomarker from each individual, during the first 180 days after symptom onset
468 were extracted for further analysis. Plasma samples used for HA analysis were collected at each
469 timepoint in 6 ml EDTA tubes (BD Diagnostics).

470

471 **Measurement of hyaluronan concentration in plasma samples**

472 Plasma hyaluronan (HA) concentrations were measured with a competitive HA-binding
473 protein-based enzyme-linked immunosorbent assay (ELISA)-like concentration measurement
474 kit (K-1200; Echelon Biosciences Inc., Salt Lake City, UT, USA), according to the

475 manufacturer's instructions. Samples were run in duplicate and a coefficient of variation (CV)
476 < 10% was considered acceptable. Absorbance was measured on a ThermoMultiskan Ascent
477 (Thermo Fisher Scientific, MA, USA) and plotted by polynomial regression against the
478 concentration of the standard curve.

479

480 **Lung function tests**

481 Lung function tests were conducted 3-6 months after study enrolment for non-hospitalized
482 patients, or discharge from hospital for patients hospitalized during the acute phase of illness,
483 as previously described (15). Reference values for DL_{CO} were calculated using The Global Lung
484 Function Initiative (GLI) Network guidelines.

485

486 **Assessment of hyaluronan metabolic pathways upon SARS-CoV-2 infection in an *in vitro***

487 **3D-lung model**

488 *(i) Generation of the human primary 3D-lung model*

489 Primary human bronchial epithelial cells (HBEC) were isolated from proximal airway tissue
490 obtained with informed consent from two patients, who underwent thoracic surgery at the
491 University Hospital, Umeå, Sweden (ethical permission approved by the Regional Swedish
492 Ethical Review Authority in Umeå). HBECs were grown and differentiated at an air-liquid
493 interface (ALI) forming an *in vitro* 3D-lung model as previously described (16). In short,
494 HBECs were grown and differentiated on 6.5 mm semipermeable transwell inserts (0.4 µm
495 Pore Polyester Membrane Insert, Corning) and after two weeks at air-liquid interface (ALI) the
496 cultures reached full differentiation, which was assessed using light microscopy focusing on
497 epithelial morphology, presence of ciliated cells, and mucus production along with
498 immunofluorescence staining for ciliated cells (acetylated-tubulin, T6793, Sigma) and goblet
499 cells (muc5AC, Ab-1 (45M1), #MS-145-P, ThermoFisher).

500 *(ii) Betamethasone treatment*

501 Fully differentiated HBEC-ALI cultures were either mock treated or treated with
502 betamethasone (Alfasigma) 20 h prior to infection by addition of 700 μ l fresh basal media
503 containing 0.3 μ M betamethasone. For study outline see figure 4A. Shortly before infection,
504 the basal media was exchanged once more and betamethasone was replenished in the treated
505 wells. Betamethasone was replenished every 24 h post infection.

506 *(iii) SARS-CoV-2 infection*

507 The clinical isolate SARS-CoV-2/01/human/2020/SWE (GeneBank accession no.
508 MT093571.1) was kindly provided by the Public Health Agency of Sweden. Vero E6 cells were
509 cultured in Dulbecco's modified Eagle's medium (DMEM, D5648 Sigma) supplemented with
510 5% FBS (HyClone), 100 U/mL penicillin and 100 μ g/ml streptomycin (PeSt, HyClone) at 37°C
511 in 5% CO₂. Propagation of the virus was done once in Vero E6 cells for 72 h and titration was
512 done by plaque assay. The apical side of the HBEC ALI-cultures were rinsed three times with
513 warm PBS shortly before infection. 1.5×10^4 plaque forming units (PFU) of SARS-CoV-2 was
514 added to the apical compartment in a total volume of 100 μ l infection medium (DMEM / PeSt),
515 corresponding to an approximate multiplicity of infection (MOI) of 0.05. The HBEC ALI-
516 cultures were incubated at 37°C and 5% CO₂ for 2.5 h before the inoculum was removed and
517 the cultures were washed with PBS to remove residual medium.

518 *(iv) Sample collection*

519 Accumulated progeny virus and secretions were collected from the apical side of the HBEC
520 ALI-cultures every 24 h by addition of 100 μ l warm PBS to the apical chamber followed by a
521 1 h incubation at 37°C and 5% CO₂. The collected samples were stored at -80°C until RNA
522 extraction. The progression of the infection was monitored for four days (96 h post infection).

523

524 *(iv) Virus quantification by qPCR*

525 Viral RNA secreted from HBEC ALI-cultures was extracted from 50 µl of the apical samples
526 using the QIAmp Viral RNA kit (Qiagen) following the manufacturer's instructions, and cDNA
527 was synthesized from 10 µl of eluted RNA. RT-qPCR for SARS-CoV-2 RNA was performed
528 in duplicates on a StepOnePlus™ Real-Time PCR System (Applied Biosystems) using the
529 qPCRBIO Probe Mix Hi-ROX (PCR biosystems) and primers (Forward:
530 GTCATGTGTGGCGGTTCACT, Reverse: CAACACTATTAGCATAAGCAGTTGT) and
531 probe (CAGGTGGAACCTCATCAGGAGATGC) specific for viral RdRp.

532

533 **Transcriptomics, total RNA sequencing**

534 At 96 h post infection the mock treated (n=3), infected (n=3) and infected + betamethasone
535 treated (n=3) HBEC ALI-cultures were washed three times on both sides with PBS. The HBEC
536 ALI-cultures were then lysed and RNA extraction was done using the NucleoSpin RNA II kit
537 (Macherey-Nagel) following the manufacturer's instructions. RNA-seq libraries were prepared
538 using the Smart-seq2 method, and sequenced on an Illumina NextSeq 500 (75PE, v2.5 High
539 Output kit). STAR 2.7.1a was used to align the reads against a reference genome consisting of
540 GRCh38 and Sars_cov_2.ASM985889v3. A gene expression table was produced using
541 featureCounts (36). Differential expression analysis was performed using DESeq2 (37).

542

543 **Cytokine quantification**

544 At 96 h post infection, samples were collected from the basal chambers of each of the HBEC
545 ALI-cultures. The samples were inactivated with Triton X-100 at a final concentration of 1%
546 followed by incubation at room temperature for 3 h. The levels of 45 cytokines were quantified
547 by Proximity Extension Assay (Olink Target 48 Cytokine panel at Affinity Proteomics Uppsala,

548 SciLifeLab Sweden), which gives absolute (pg/mL) and relative (normalized protein
549 expression, NPX) concentration measurements of 45 pre-selected cytokines.

550

551 **Quantification of HA synthases and hyaluronidases by qPCR**

552 Total RNA from cells were extracted using the Nucleo-Spin RNA II kit (Macherey-Nagel).
553 1000 ng of RNA was used as input for cDNA synthesis using High-capacity cDNA Reverse
554 Transcription kit (Thermo Fisher). Cellular HA synthases (*HAS1*, 2 and 3) and hyaluronidases
555 (*HYAL1* and 2) were quantified using qPCRBIO SyGreen mix Hi-ROX (PCR Biosystems) and
556 QuantiTect primer assay (Qiagen, *HAS1*;QT02588509, *HAS2*;QT00027510,
557 *HAS3*;QT00014903, *HYAL1*;QT01673413, *HYAL2*;QT00013363) with actin as a housekeeping
558 gene (QT01680476) and run on a StepOnePlus™ Real-Time PCR System (Applied
559 Biosystems).

560

561 **Measurement of HA concentration in apical secretions from HBEC ALI-cultures**

562 Apical secretions from HBEC ALI-cultures were collected at 120 h post infection and HA
563 concentrations were measured with a Hyaluronic Acid AlphaScreen Assay (K-5800; Echelon
564 Biosciences Inc., Salt Lake City, UT, USA), according to the manufacturer's instructions.
565 AlphaScreen beads from the Histidine (Nickel Chelate) Detection Kit (PerkinElmer, MA, USA)
566 was used. Chemiluminescent emission was measured on a SpectraMax i3x (Molecular Devices,
567 CA, USA) and plotted by polynomial regression against the concentration of the standard curve.

568

569 **Statistical analysis**

570 Statistical analysis was performed with Graphpad Prism 9 and Jamovi version 2.2.5 (The
571 jamovi project (2021)). jamovi (Version 1.6). Retrieved from <https://www.jamovi.org>).

572 Descriptive variables of the patient cohort were analyzed by Mann-Whitney U-test

573 (continuous variables) and Fisher's exact test or Chi2 test (dichotomous variables). Missing
574 data were handled by complete case analysis. No correction for multiple testing was
575 performed. Multiple linear regression was used to explore the association between DL_{CO} and
576 HA levels in plasma during the acute illness and the convalescent phase. Independent variables
577 were sex, chronic lung disease, cardiovascular disease, hypertension, diabetes, smoking
578 (current or previous), obesity (BMI ≥ 30), severity of COVID-19 (mild or severe), and age
579 (20-59 and 60-89 years). The log transformation was used to address skewed data in HA.

580

581 **Data availability**

582 The CoVUm data cannot be made publicly available, according to Swedish data protection laws
583 and the terms of ethical approval that were stipulated by the Ethical Review Authority of
584 Sweden. Access to data from the CoVUm database is organized according to a strict data access
585 procedure, to comply with Swedish law. For all types of access, a research proposal must be
586 submitted to the corresponding authors for evaluation. After evaluation, data access is
587 contingent on vetting by the Ethical Review Authority of Sweden, according to the Act
588 (2003:460) concerning the Ethical Review of Research Involving Humans.

589

590 **Acknowledgement:**

591 The authors thank the team at Affinity Proteomics Uppsala, SciLifeLab Sweden, for providing
592 assistance with Olink assays. We acknowledge our study nurses Ida-Lisa Persson and Anna
593 Kauppi at the Department of Infectious Diseases in Umeå and Christine Degner, Anna Segerås
594 and Lena Irvhage in Örebro, and the personnel at the Clinical Research Center at Umeå
595 University Hospital and Örebro University Hospital for enrolment and sampling of study
596 participants. We also acknowledge Umeå Center for Microbial Research (UCMR); the
597 Biochemical Imaging Center at Umeå University (BICU), and the National Microscopy

598 Infrastructure for microscopy support (NMI; VR-RFI 2019-00217). Figure 1A, 2A, 4A and 5
599 were created using BioRender.com.

600 REFERENCES


- 601 1. Gavriatopoulou M, Korompoki E, Fotiou D, Ntanasis-Stathopoulos I, Psaltopoulou T,
602 Kastritis E, Terpos E, Dimopoulos MA. Organ-specific manifestations of COVID-19
603 infection. *Clin Exp Med* 2020; 20: 493-506.
- 604 2. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai
605 C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-
606 19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020; 8: 420-
607 422.
- 608 3. Laurent TC, Laurent UB, Fraser JR. The structure and function of hyaluronan: An overview.
609 *Immunol Cell Biol* 1996; 74: A1-7.
- 610 4. Delmage JM, Powars DR, Jaynes PK, Allerton SE. The selective suppression of
611 immunogenicity by hyaluronic acid. *Ann Clin Lab Sci* 1986; 16: 303-310.
- 612 5. Petrey AC, de la Motte CA. Hyaluronan, a crucial regulator of inflammation. *Front Immunol*
613 2014; 5: 101.
- 614 6. Albeiroti S, Soroosh A, de la Motte CA. Hyaluronan's Role in Fibrosis: A Pathogenic Factor
615 or a Passive Player? *Biomed Res Int* 2015; 2015: 790203.
- 616 7. Hallgren R, Samuelsson T, Laurent TC, Modig J. Accumulation of hyaluronan (hyaluronic
617 acid) in the lung in adult respiratory distress syndrome. *Am Rev Respir Dis* 1989; 139:
618 682-687.
- 619 8. Hellman U, Karlsson MG, Engstrom-Laurent A, Cajander S, Dorofte L, Ahlm C, Laurent C,
620 Blomberg A. Presence of hyaluronan in lung alveoli in severe Covid-19: An opening
621 for new treatment options? *J Biol Chem* 2020; 295: 15418-15422.
- 622 9. Kratochvil MJ, Kaber G, Demirdjian S, Cai PC, Burgener EB, Nagy N, Barlow GL, Popescu
623 M, Nicolls MR, Ozawa MG, Regula DP, Pacheco-Navarro AE, Yang S, de Jesus Perez
624 VA, Karmouty-Quintana H, Peters AM, Zhao B, Buja ML, Johnson PY, Vernon RB,
625 Wight TN, Stanford C-BSG, Milla CE, Rogers AJ, Spakowitz AJ, Heilshorn SC,
626 Bollyky PL. Biochemical, biophysical, and immunological characterization of
627 respiratory secretions in severe SARS-CoV-2 infections. *JCI Insight* 2022; 7.
- 628 10. Ding M, Zhang Q, Li Q, Wu T, Huang YZ. Correlation analysis of the severity and clinical
629 prognosis of 32 cases of patients with COVID-19. *Respir Med* 2020; 167: 105981.
- 630 11. Donlan AN, Sutherland TE, Marie C, Preissner S, Bradley BT, Carpenter RM, Sturek JM,
631 Ma JZ, Moreau GB, Donowitz JR, Buck GA, Serrano MG, Burgess SL, Abhyankar
632 MM, Mura C, Bourne PE, Preissner R, Young MK, Lyons GR, Loomba JJ, Ratcliffe
633 SJ, Poulter MD, Mathers AJ, Day AJ, Mann BJ, Allen JE, Petri WA, Jr. IL-13 is a driver
634 of COVID-19 severity. *JCI Insight* 2021; 6.
- 635 12. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N,
636 Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D,
637 Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K,
638 Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients
639 with Covid-19. *N Engl J Med* 2021; 384: 693-704.
- 640 13. Ernst G, Lompardia S, Cordo Russo R, Gentilini V, Venturiello S, Galindez F, Grynblat P,
641 Hajos SE. Corticosteroid administration reduces the concentration of hyaluronan in
642 bronchoalveolar lavage in a murine model of eosinophilic airway inflammation.
643 *Inflamm Res* 2012; 61: 1309-1317.
- 644 14. Engstrom-Laurent A, Hallgren R. Circulating hyaluronate in rheumatoid arthritis:
645 relationship to inflammatory activity and the effect of corticosteroid therapy. *Ann*
646 *Rheum Dis* 1985; 44: 83-88.
- 647 15. Bjorsell T, Sundh J, Lange A, Ahlm C, Forsell MNE, Tevell S, Blomberg A, Edin A,
648 Normark J, Cajander S. Risk factors for impaired respiratory function post COVID-19:

- 649 A prospective cohort study of nonhospitalized and hospitalized patients. *J Intern Med*
650 2023.
- 651 16. Khan AI, Kerfoot SM, Heit B, Liu L, Andonegui G, Ruffell B, Johnson P, Kubes P. Role
652 of CD44 and hyaluronan in neutrophil recruitment. *J Immunol* 2004; 173: 7594-7601.
- 653 17. Characterisation WHO GotC, Management of C-i. A minimal common outcome measure
654 set for COVID-19 clinical research. *Lancet Infect Dis* 2020; 20: e192-e197.
- 655 18. Rosendal E, Mihai IS, Becker M, Das D, Frangsmyr L, Persson BD, Rankin GD, Groning
656 R, Trygg J, Forsell M, Ankarklev J, Blomberg A, Henriksson J, Overby AK, Lenman
657 A. Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections.
658 *mBio* 2022: e0089222.
- 659 19. Zaack LM, Scheibner D, Sehl J, Muller M, Hoffmann D, Beer M, Abdelwhab EM,
660 Mettenleiter TC, Breithaupt A, Finke S. Light Sheet Microscopy-Assisted 3D Analysis
661 of SARS-CoV-2 Infection in the Respiratory Tract of the Ferret Model. *Viruses* 2021;
662 13.
- 663 20. Truffaut L, Demey L, Bruyneel AV, Roman A, Alard S, De Vos N, Bruyneel M. Post-
664 discharge critical COVID-19 lung function related to severity of radiologic lung
665 involvement at admission. *Respir Res* 2021; 22: 29.
- 666 21. Bjermer L, Lundgren R, Hallgren R. Hyaluronan and type III procollagen peptide
667 concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. *Thorax*
668 1989; 44: 126-131.
- 669 22. Hernnas J, Nettelbladt O, Bjermer L, Sarnstrand B, Malmstrom A, Hallgren R. Alveolar
670 accumulation of fibronectin and hyaluronan precedes bleomycin-induced pulmonary
671 fibrosis in the rat. *Eur Respir J* 1992; 5: 404-410.
- 672 23. Tolg C, Hamilton SR, Zalinska E, McCulloch L, Amin R, Akentieva N, Winnik F, Savani
673 R, Bagli DJ, Luyt LG, Cowman MK, McCarthy JB, Turley EA. A RHAMM mimetic
674 peptide blocks hyaluronan signaling and reduces inflammation and fibrogenesis in
675 excisional skin wounds. *Am J Pathol* 2012; 181: 1250-1270.
- 676 24. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and
677 turnover. *J Intern Med* 1997; 242: 27-33.
- 678 25. Li W, Yang S, Xu P, Zhang D, Tong Y, Chen L, Jia B, Li A, Lian C, Ru D, Zhang B, Liu
679 M, Chen C, Fu W, Yuan S, Gu C, Wang L, Li W, Liang Y, Yang Z, Ren X, Wang S,
680 Zhang X, Song Y, Xie Y, Lu H, Xu J, Wang H, Yu W. SARS-CoV-2 RNA elements
681 share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer
682 network. *EBioMedicine* 2022; 76: 103861.
- 683 26. Hascall VC, Wang A, Tammi M, Oikari S, Tammi R, Passi A, Vigetti D, Hanson RW, Hart
684 GW. The dynamic metabolism of hyaluronan regulates the cytosolic concentration of
685 UDP-GlcNAc. *Matrix Biol* 2014; 35: 14-17.
- 686 27. Codo AC, Davanzo GG, Monteiro LB, de Souza GF, Muraro SP, Virgilio-da-Silva JV,
687 Prodonoff JS, Carregari VC, de Biagi Junior CAO, Crunfli F, Jimenez Restrepo JL,
688 Vendramini PH, Reis-de-Oliveira G, Bispo Dos Santos K, Toledo-Teixeira DA, Parise
689 PL, Martini MC, Marques RE, Carmo HR, Borin A, Coimbra LD, Boldrini VO, Brunetti
690 NS, Vieira AS, Mansour E, Ulaf RG, Bernardes AF, Nunes TA, Ribeiro LC, Palma AC,
691 Agrela MV, Moretti ML, Sposito AC, Pereira FB, Velloso LA, Vinolo MAR, Damasio
692 A, Proenca-Modena JL, Carvalho RF, Mori MA, Martins-de-Souza D, Nakaya HI,
693 Farias AS, Moraes-Vieira PM. Elevated Glucose Levels Favor SARS-CoV-2 Infection
694 and Monocyte Response through a HIF-1alpha/Glycolysis-Dependent Axis. *Cell Metab*
695 2020; 32: 437-446 e435.
- 696 28. Laviada-Molina HA, Leal-Berumen I, Rodriguez-Ayala E, Bastarrachea RA. Working
697 Hypothesis for Glucose Metabolism and SARS-CoV-2 Replication: Interplay Between

- 698 the Hexosamine Pathway and Interferon RF5 Triggering Hyperinflammation. Role of
699 BCG Vaccine? *Front Endocrinol (Lausanne)* 2020; 11: 514.
- 700 29. Tang J, Chen L, Qin ZH, Sheng R. Structure, regulation, and biological functions of TIGAR
701 and its role in diseases. *Acta Pharmacol Sin* 2021; 42: 1547-1555.
- 702 30. Zhang W, Wang G, Xu ZG, Tu H, Hu F, Dai J, Chang Y, Chen Y, Lu Y, Zeng H, Cai Z,
703 Han F, Xu C, Jin G, Sun L, Pan BS, Lai SW, Hsu CC, Xu J, Chen ZZ, Li HY, Seth P,
704 Hu J, Zhang X, Li H, Lin HK. Lactate Is a Natural Suppressor of RLR Signaling by
705 Targeting MAVS. *Cell* 2019; 178: 176-189 e115.
- 706 31. Yang S, Ling Y, Zhao F, Li W, Song Z, Wang L, Li Q, Liu M, Tong Y, Chen L, Ru D,
707 Zhang T, Zhou K, Zhang B, Xu P, Yang Z, Li W, Song Y, Xu J, Zhu T, Shan F, Yu W,
708 Lu H. Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently
709 blocking COVID-19 progression. *Signal Transduct Target Ther* 2022; 7: 91.
- 710 32. Ahmad I, Edin A, Granvik C, Kumm Persson L, Tevell S, Mansson E, Magnuson A,
711 Marklund I, Persson IL, Kauppi A, Ahlm C, Forsell MNE, Sundh J, Lange A, Cajander
712 S, Normark J. High prevalence of persistent symptoms and reduced health-related
713 quality of life 6 months after COVID-19. *Front Public Health* 2023; 11: 1104267.
- 714 33. Roffman CE, Buchanan J, Allison GT. Charlson Comorbidities Index. *J Physiother* 2016;
715 62: 171.
- 716 34. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
717 capture (REDCap)--a metadata-driven methodology and workflow process for
718 providing translational research informatics support. *J Biomed Inform* 2009; 42: 377-
719 381.
- 720 35. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua
721 G, Delacqua F, Kirby J, Duda SN, Consortium RE. The REDCap consortium: Building
722 an international community of software platform partners. *J Biomed Inform* 2019; 95:
723 103208.
- 724 36. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for
725 assigning sequence reads to genomic features. *Bioinformatics* 2014; 30: 923-930.
- 726 37. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
727 RNA-seq data with DESeq2. *Genome Biol* 2014; 15: 550.


728

729 **FIGURES**



730

731 **Figure 1. Light sheet fluorescent microscopy (LSFM) of biopsies from deceased COVID-**
732 **19 patients displays a reduced alveolar surface.** A) Schematic overview of LFSM procedure
733 with tissue biopsies from healthy donors (n=4), deceased COVID-19 patients (n=3) and
734 recovered COVID-19 patient (n=1). B-D) Maximum intensity projections of one representative
735 biopsy from each patient group. Scale bar in D is 500 μm . E-G) LFSM sections and
736 magnifications showing the alveolar structure in each patient group. Scale bar in G is 500 μm
737 and scalebar in G' is 100 μm . H) Size distribution of alveolar diameter measured in LFSM
738 sections, ten random diameter measurements in five different z planes from each patient. I-K)
739 Iso-surfaced empty space in the lung biopsies as a proxy for alveolar volume. Scalebar in K is
740 400 μm and scalebar in K' is 100 μm . L) Quantification of the surface volume surrounding the
741 empty space as a proxy for alveolar surface volume. Statistical significance was calculated by
742 unpaired t-test (***) $p < 0.001$).




743

744 **Figure 2. Lung necropsies and lung aspirates from severe COVID-19 patients show large**

745 **amounts of hyaluronan (HA) and a high degree of HA fragmentation. A) Schematic**


746 **overview of collection of patient samples for HA analysis. B) Lung biopsies from the upper and**

747 lower left lobe of five deceased COVID-19 patients were stained for HA. Scale bar is 1000 μm .
748 C) Collagen and HA staining in lung biopsies from healthy lung tissue (scale bar is 200 μm)
749 and from a deceased COVID-19 patient (scale bar is 100 μm). The COVID-19 lung biopsy
750 shows areas with no alveoli structures. D) HA was isolated from the lung biopsies in B (n=5)
751 and a size distribution analysis was performed with gas-phase electrophoretic mobility
752 molecular analysis (GEMMA). Shown is an average of all five patients. High molecular weight
753 HA with a known molecular size of 30 kDa was included as control. HA was also isolated and
754 subjected to size analysis by GEMMA from E) nasopharyngeal aspirate and F) endotracheal
755 aspirate collected from three severe COVID-19 patients and displayed individually for each
756 patient.



757
758 **Figure 3. High concentrations of hyaluronan (HA) in plasma are associated with COVID-**
759 **19 severity and long-term lung impairment.** A) HA concentrations in plasma from patients
760 with severe and mild COVID-19 compared to controls (Ctrl). Samples were taken during the
761 acute phase (0-4 weeks from disease onset) and again during the convalescent phase of the
762 disease (≥ 12 weeks). HA concentrations were determined by ELISA. B-C) HA concentrations
763 in plasma during the acute phase grouped based on severity and B) sex or C) age. Each dot
764 represents one patient, and the line represents the median. Severity was based on WHO Clinical

765 Progression Scale (WHO-CPS) with patients requiring high-flow nasal oxygen treatment and/or
766 admission to the intensive care unit during the acute phase of illness classified as “severe”,
767 corresponding to WHO-CPS 6-9, and all other patients as “mild”, WHO-CPS 1-5. Statistical
768 significance was calculated by Mann-Whitney U-test (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). D-
769 E) The percentage of predicted values of diffusion capacity (DL_{CO}) related to HA
770 concentrations in plasma in D) the acute phase or E) the convalescent phase divided by sex and
771 disease severity. F-G) The percentage of predicted values of DL_{CO} related to HA concentrations
772 in plasma in D) the acute phase or E) the convalescent phase divided by age and disease
773 severity.




775 **Figure 4. Inflammatory response and effect of corticosteroid treatment in a SARS-CoV-2**
776 **infected 3D-lung model.** A) Schematic overview of the primary 3D-lung model that was
777 infected with SARS-CoV-2 in the presence or absence of corticosteroids to investigate the
778 effect on inflammation and hyaluronan metabolism. B) The lung cultures based on
779 differentiated primary human bronchial epithelial cells at an air-liquid interface were pretreated
780 with/without betamethasone (Beta) in the basal media for 20 h prior to infection with SARS-
781 CoV-2 (multiplicity of infection=0.5). The accumulated viral release from the apical side of the
782 cultures was quantified by qPCR at indicated timepoints. C-D) Volcano plot showing
783 differentially expressed genes between C) infected vs uninfected (mock) lung cultures and D)
784 infected lung cultures with betamethasone vs without betamethasone treatment. The statistical
785 p -value ($-\log_{10}$) is plotted against the fold change in gene expression (\log_2). Dotted lines
786 highlight the significance cut off corresponding to a fold change of 1.3 and p -value=0.05. E)
787 Heatmap displaying the mean expression (\log_2) of the overlapping genes in uninfected, infected
788 and infected + betamethasone-treated lung cultures. F) Cytokine levels in basolateral samples
789 from HBEC ALI-cultures collected at 96 h post infection analyzed by Proximity Extension
790 Assay (Olink). The gene expression levels of HA synthases G) *HAS1*, H) *HAS2* and I) *HAS3*
791 along with the hyaluronidases J) *HYAL1* and K) *HYAL2* were determined by qPCR 120 h post
792 SARS-CoV-2 infection of lung cultures from two different donors (D1 and D2). L) HA
793 concentrations were determined by ELISA in apical secretions from lung cultures 120 h post
794 infection. Mean values and SEM are shown, statistical significance was calculated by unpaired
795 t-test (* $p < 0.05$, ** $p < 0.01$ *** $p < 0.001$).

796

797

798

799



801 **Figure 5. The effect of SARS-CoV-2 and betamethasone on cellular pathways regulating**
802 **IFN-I responses and hyaluronan (HA) production in a human *in vitro* 3D-lung model.**
803 Schematic presentation of a cell infected with SARS-CoV-2 with or without betamethasone
804 treatment and affected cellular pathways regulating A) the IFN-I response and B) HA
805 production. The left side of the gene shows the effect on gene expression upon SARS-CoV-2
806 infection, and the right side shows effect of betamethasone treatment in infected lung cultures.
807 Blue color corresponds to an increase in gene expression and yellow indicates a decrease in
808 gene expression. Viral genes are represented by dotted lines.

809 **TABLES**

810 **Table 1. Demography and characteristics of COVID-19 patients.**

Patient characteristics	Severe (N=37)	Mild (N=66)	p-value
Demography			
Age, Years	58.0 (46.0-64.0)	54.5 (43.3-61.5)	0.584
Sex, Female N (%)	11 (29.7)	31 (47.0)	0.112
BMI	30.5 (27.6-33.3)	26.3 (24.0-28.9)	<0.001
Obesity N (%)	20 (54.1)	15 (22.7)	0.002
Comorbidities			
Diabetes N (%)	4 (10.8)	5 (7.6)	0.719
Hypertension N (%)	12 (32.4)	17 (25.8)	0.500
Cardiovascular disease^a N (%)	4 (10.8)	11 (16.7)	0.564
Chronic pulmonary disorder^b N (%)	8 (21.6)	11 (16.7)	0.600
Autoimmune disease N (%)	2 (5.4)	5 (7.6)	1.000
Charlson comorbidity index	0 (0-1.0)	0 (0-0.8)	0.584
Smoking^c			
Smoker N (%)	1 (2.8)	1 (1.7)	0.384
Ex-smoker N (%)	13 (36.1)	14 (23.7)	
Laboratory findings			
C-reactive protein, max (mg/L)^d	166 (84.5-278)	12 (3.1-76.0)	<0.001
Hemoglobin, min g/L^e	126 (105-133)	134 (121-144)	0.004
White bloodcell count, max (10e9/L)^e	11.9 (8.9-16.1)	6.9 (5.4-8.0)	<0.001
Neutrophil count, max (10e9/L)^e	9.3 (6.0-12.3)	4.15 (2.9-5.1)	<0.001
Lymphocyte count, max (10e9/L)^e	2.3 (1.7-2.3)	2.05 (1.7-2.4)	0.061
Platelet count, min (10e9/L)^f	193 (167-233)	187 (134-232)	0.251
P-Creatinine, max (μmol/L)^e	79 (68.0-98.0)	77.5 (70.3-90.0)	0.975
Interleukin-6 max (ng/L)^g	141 (27.3-353)	22 (14.3-35.8)	0.002
Treatment and respiratory support			
Corticosteroid treatment N (%)	32 (86.5)	4 (6.1)	<0.001
Remdesivir treatment N (%)	15 (40.5)	3 (4.5)	<0.001
Invasive mechanical ventilation N (%)	8 (21.6)	0 (0)	<0.001

811 Descriptive data of the patient cohort. All values presented as median and interquartile range if
812 not otherwise stated.

813 Differences between groups analyzed by Mann-Whitney U-test (continuous variables) and
814 Fisher's exact test (dichotomous variables), except when otherwise stated. No correction for
815 multiple testing was performed.


816 ^aIncluding: Heart failure, ischemic heart disease, peripheral arterial insufficiency, deep venous
817 thrombosis, and pulmonary embolism.

818 ^bIncluding: Asthma and chronic obstructive pulmonary disease.

819 ^cN=95, analysed by Chi² test, ^dN=91, ^eN=93, ^fN=92, ^gN=66


820

821 SUPPLEMENTARY INFORMATION



822

823 **Supplementary figure 1. Light sheet fluorescent microscopy of biopsies from deceased**
824 **COVID-19 patients and healthy donors.** Maximum intensity projections of three healthy
825 donors and two COVID-19 necropsies, scale bar is 500 μm .



826

827 **Supplementary figure 2. Neutrophil infiltration of COVID-19 lung necropsy.** Confocal
828 images on paraffin sections from healthy and COVID-19 lung biopsies stained with Dapi (blue)
829 and neutrophil elastase (green). Representative pictures from imaged biopsies, scalebar is 100
830 μm .

831 **Supplementary Table 1.**

832

Hyaluronan in the acute phase as a predictor for reduced diffusion capacity.			
		DL_{co}%pred	
Variables	N (%)	β -coefficient (95% CI)	p
HA acute phase (log 2)		-5.62 (-11.01 to -0.22)	0.042
Sex			
Male	41 (58.6)	ref	
Female	29 (41.4)	3.74 (-6.06 to 13.53)	0.448
Chronic lung disease	14 (20)	-3.58 (-16.54 to 9.37)	0.582
Cardiovascular disease	10 (14.3)	-8.89 (-23.74 to 5.97)	0.236
Hypertension	19 (27.1)	-10.45 (-22.58 to 1.68)	0.090
Diabetes	4 (5.7)	4.69 (-15.72 to 25.11)	0.647
Smoker or previous smoker	20 (28.6)	-1.74 (12.24 to 8.75)	0.741
Obesity	23 (32.9)	1.27 (-9.27 to 11.81)	0.810
Severity of COVID-19			
Mild disease	42 (60)	ref	
Severe disease	28 (40)	-8.0 (-19.77 to 3.76)	0.179
Age groups (years)			
20-59	12 (17.1)	ref	
60-89	31 (44.3)	-0.08 (-11.46 to 11.30)	0.988
Multiple linear regression calculated for the dependent variable DL _{co} % of predicted (DL _{co} %pred). Reported with β -coefficient and 95% confidence interval (CI). DL _{co} , diffusion capacity; HA, hyaluronan acid; ref, reference group. Obesity defined as BMI \geq 30. Adjusted R ² = 0.238, p < 0.003. Significance set at p < 0.05.			

851 **Supplementary Table 2.**

Hyaluronan in the convalescent phase as a predictor for reduced diffusion capacity.			
		DL_{co}%pred	
Variables	N (%)	β-coefficient (95% CI)	p
HA convalescent phase (log 2)		-9.51 (-18.21 to -0.82)	0.033
Sex			
Male	41 (58.6)	ref	
Female	29 (41.4)	4.62 (-5.45 to 14.68)	0.361
Chronic lung disease	14 (20)	0.68 (-14.63 to 15.99)	0.929
Cardiovascular disease	10 (14.3)	-17.64 (-33.48 to -1.80)	0.030
Hypertension	19 (27.1)	-10.03 (-22.88 to 2.83)	0.123
Diabetes	4 (5.7)	-2.22 (-28.57 to 24.13)	0.866
Smoker or previous smoker	20 (28.6)	4.40 (-6.15 to 14.96)	0.406
Obesity	23 (32.9)	3.53 (-7.95 to 15.01)	0.539
Severity of COVID-19			
Mild disease	42 (60)	ref	
Severe disease	28 (40)	-13.99 (-25.05 to -2.93)	0.014
Age groups (years)			
20-59	12 (17.1)	ref	
60-89	31 (44.3)	4.14 (-7.58 to 15.87)	0.481
Multiple linear regression calculated for the dependent variable DL _{co} % of predicted (DL _{co} %pred). Reported with β-coefficient and 95% confidence interval (CI). DL _{co} , diffusion capacity; HA, hyaluronan acid; ref, reference group. Obesity defined as BMI ≥ 30. Adjusted R ² = 0.304, p < 0.001. Significance set at p < 0.05.			

852